Protalix to raise $20.6 million, as it responds to FDA Gaucher's rejection
This article was originally published in Scrip
Executive Summary
The Israeli firm Protalix BioTherapeutics has announced the pricing of four million shares of its common stock at $5.50 per share. The firm expects net proceeds of about $20.6 million.